13 11 20

Information and support

  • Get informed
  • Get support
  • Cut my risk
  • Get involved
  • Research
  • NIVORAD

    Acronym: 

    NIVORAD

    ACTRN/NCT /ethics: 

    ACTRN12616000352404

    Scientific title: 

    A randomised phase 2 trial of nivolumab and stereotactic ablative body radiotherapy in advanced non-small cell lung cancer, progressing after first or second line chemotherapy

    Summary of trial and patient characteristics

    Cancer Type Lung & mesothelioma
    Trial Type Treatment
    Phase Phase II Tumour Stream Non-Small Lung Cancer
    Age Range 18 years and older Cancer Stage Locally Recurrent or Locally Advanced
    Sex Both Anticipated Start Date 2016-05-02
    Molecular Target Anticipated End Date
    Cancer Type Lung & mesothelioma
    Trial Type Treatment
    Phase Phase II
    Age Range 18 years and older
    Sex Both
    Molecular Target
    Tumour Stream Non-Small Lung Cancer
    Cancer Stage Locally Recurrent or Locally Advanced
    Anticipated Start Date 2016-05-02
    Anticipated End Date

    Trial Summary

    A randomised phase 2 trial of nivolumab and stereotactic ablative body radiotherapy in advanced non-small cell lung cancer, progressing after first or second line chemotherapy

    Lay Summary

    A randomised phase 2 trial of nivolumab and stereotactic ablative body radiotherapy in advanced non-small cell lung cancer, progressing after first or second line chemotherapy

    Sponsor / Cooperative group

    University of Sydney

    Participating Hospitals

    Hospital Clinical Trial Coordinator Email Phone Principal Investigator Recruitment Status
    Flinders Medical Centre Alex Scott-Hoy alex.scott-hoy@sa.gov.au 08 8204 4830 Chris Karapetis Recruiting